Aytu Biopharma (AYTU) Change in Account Payables (2014 - 2026)

Aytu Biopharma (AYTU) has 10 years of Change in Account Payables data on file, last reported at -$1.0 million in Q1 2026.

• Change in Account Payables for Q1 2026 came in at -$1.0 million, down 362.56% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.8 million (down 198.17% YoY), and the FY2025 annual result was $287000.0, up 113.82% from the prior year.
• Change in Account Payables rose to -$1.0 million in Q1 2026 per AYTU's latest filing, from -$1.1 million in the prior quarter.
• Over five years, Change in Account Payables peaked at $4.6 million in Q1 2023 and troughed at -$4.8 million in Q1 2022.
• A 5-year average of -$246941.2 and a median of $134000.0 in 2024 frame the typical range for Change in Account Payables.
• The sharpest annual moves came in 2024 and 2025: Change in Account Payables soared 243.87% in 2024, then sank 1174.63% in 2025.
• A 5-year view of Change in Account Payables shows it stood at -$4.4 million in 2022, then gained by 9.42% to -$4.0 million in 2023, then soared by 54.74% to -$1.8 million in 2024, then surged by 40.3% to -$1.1 million in 2025, then grew by 3.51% to -$1.0 million in 2026.
• Business Quant data shows AYTU's Change in Account Payables at -$1.0 million in Q1 2026, -$1.1 million in Q4 2025, and $1.7 million in Q3 2025.